Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;8(2):101194.
doi: 10.1016/j.esmoop.2023.101194. Epub 2023 Mar 21.

Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy

C Oing  1 , R G Bristow  2
Affiliations

Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy

C Oing et al. ESMO Open. 2023 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure CO: advisory role: secondment as clinical advisor to Astex Pharmaceuticals; speaker’s honoraria and/or advisory board participation: AstraZeneca, Ipsen, Roche, Sandoz; research funding: PharmaMar (non-financial), all outside the submitted work. RGB has declared no conflicts of interest.

References

    1. Rebello R.J., Oing C., Knudsen K.E., et al. Prostate cancer. Nat Rev Dis Primers. 2021;7:9. - PubMed
    1. Sung H., Ferlay J., Siegel R.L., et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Francini E., Gray K.P., Xie W., et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC) Prostate. 2018;78:889–895. - PMC - PubMed
    1. Parker C., Castro E., Fizazi K., et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31:1119–1134. - PubMed
    1. Fizazi K., Tran N.P., Fein L., et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20:686–700. - PubMed